The biotechnology industry has growing concerns over decisions to be taken this year by the United States Supreme Court in two cases involving the patenting of human genes and the exhaustion of patent rights in the context of easily reproducible products. Several areas of biotechnology could be affected by unfavorable decisions, provoking legal uncertainty and discouraging innovation, industry representatives said in a recent telephone conference. In the meantime, civil society stands fast in opposition.
For more information visit:
http://www.ip-watch.org/2013/02/18/monsanto-myriad-two-us-legal-cases-shaking-biotechnology-industries/#more-26747
